Cite
MLA Citation
Christian Klein et al.. “Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.” Oncoimmunology, vol. 6, 2017, p. . http://access.bl.uk/ark:/81055/vdc_100044868367.0x000024